CABALETTA BIO, INC. Other Research and Development Expense
CABALETTA BIO, INC. (CABA) reported Other Research and Development Expense of $1.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-13
- CABALETTA BIO, INC. other research and development expense for the quarter ending 2026-06-30 was $1.16M, a 52.37% increase year-over-year.
- CABALETTA BIO, INC. other research and development expense for the quarter ending 2026-03-31 was $812.00K, a 49.54% increase year-over-year.
- CABALETTA BIO, INC. other research and development expense for the quarter ending 2025-12-31 was $689.00K, a 13.14% increase year-over-year.
- CABALETTA BIO, INC. other research and development expense for the quarter ending 2025-09-30 was $578.00K, a 31.66% increase year-over-year.
- CABALETTA BIO, INC. other research and development expense for fiscal 2025 was $2.57M, a 15.98% increase from fiscal 2024.
- CABALETTA BIO, INC. other research and development expense for fiscal 2024 was $2.21M, a 60.51% increase from fiscal 2023.
- CABALETTA BIO, INC. other research and development expense for fiscal 2023 was $1.38M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.16M 10-Q · filed 2026-08-13 | $1.97M 10-Q · filed 2026-08-13 | $2.66M derived: sum of 3 quarters · filed 2026-08-13 | $3.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $812.00K 10-Q · filed 2026-05-14 | $1.50M derived: sum of 2 quarters · filed 2026-05-14 | $2.08M derived: sum of 3 quarters · filed 2026-05-14 | $2.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.27M derived: sum of 2 quarters · filed 2026-03-23 | $2.03M derived: sum of 3 quarters · filed 2026-08-13 | $2.57M 10-K · filed 2026-03-23 |
| 2025-09-30 | $578.00K 10-Q · filed 2025-11-10 | $1.34M derived: sum of 2 quarters · filed 2026-08-13 | $1.88M 10-Q · filed 2025-11-10 | $2.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $760.00K 10-Q · filed 2026-08-13 | $1.30M 10-Q · filed 2026-08-13 | $1.91M derived: sum of 3 quarters · filed 2026-08-13 | $2.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $543.00K 10-Q · filed 2026-05-14 | $1.15M derived: sum of 2 quarters · filed 2026-05-14 | $1.59M derived: sum of 3 quarters · filed 2026-05-14 | $2.39M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $609.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.05M derived: sum of 2 quarters · filed 2026-03-23 | $1.85M derived: sum of 3 quarters · filed 2026-03-23 | $2.21M 10-K · filed 2026-03-23 |
| 2024-09-30 | $439.00K 10-Q · filed 2025-11-10 | $1.24M derived: sum of 2 quarters · filed 2025-11-10 | $1.61M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $799.00K 10-Q · filed 2025-08-07 | $1.17M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $369.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $1.38M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |